Silo Pharma, Inc. (Nasdaq: SILO) ('Silo” or 'the Company), a diversified developmental-stage biopharmaceutical and ...
GlobalData on MSN
FDA unveils new pathway to usher bespoke therapies to market
The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
As 2026 approaches, now is the time to reflect on the victories from the year and the lessons to be taken moving forward.
Evotec SE ( EVO) on Wednesday said that it has received a $5 million milestone payment from Bristol Myers Squibb ( BMY ), following the acceptance of an investigational new drug application by the U.S ...
Lexicon Pharmaceuticals targets a turnaround with sotagliflozin, LX9851, pilavapadin, and partnerships offering multiple ...
(Nasdaq: MGX) (the "Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create ...
The FDA accepted the investigational new drug application for UGN-103 in April 2024. These new positive data position the ...
The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder.
Takeda’s dengue vaccine demonstrated strong protection against infection and hospitalization for up to 7 years, findings ...
Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback